Immunic, Inc. — Earnings
Most recent reported period: FY2014 (Q1) (filed for period ending 2014-03-31) · sourced from SEC EDGAR
Next earnings (estimated): Mon, June 30, 2014 — 4324 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | — | — | — | — | — |
| 2025-09-30 | — | — | $-26M | ↓-5.0% | — |
| 2025-06-30 | — | — | $-27M | ↓-25.4% | — |
| 2025-03-31 | — | — | $-25M | ↑+13.9% | — |
| 2024-12-31 | — | — | — | — | — |
| 2024-09-30 | — | — | $-24M | ↓-7.0% | — |
| 2024-06-30 | — | — | $-21M | ↑+10.9% | — |
| 2024-03-31 | — | — | $-30M | ↓-17.1% | — |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2014 (Q1)
Revenue
$22K
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 53 quarters
margin trajectory tells the operating-leverage storyGross Margin
40.9%
Operating Margin
-53981.8%
Net Margin
-48854.5%
Go deeper
IMUX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyIMUX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics